BioCardia Reported Earnings
Wednesday, May 14, 2025 at 4:05 PM ET
BioCardia (BCDA) reported a loss of $0.59 per share on revenue of $0.00 million for the first quarter ended March 2025. The consensus revenue estimate was revenue of $0.10 million. Revenue fell 100.00% compared to the same quarter a year ago.
BioCardia, Inc. is a developer of two biotherapeutic platforms – the CardiAMP autologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogeneic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-0.59
Earnings Whisper®
-
Consensus Estimate
-
Earnings Surprise
Earnings Growth
Reported Revenue
-
Revenue Estimate
$100.00 Thou
Revenue Surprise
Revenue Growth